Viridian Therapeutics Stock Market Value
| VRDN Stock | USD 27.63 0.27 0.97% |
| Symbol | Viridian |
Will Biotechnology sector continue expanding? Could Viridian diversify its offerings? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Viridian Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.03) | Revenue Per Share | Quarterly Revenue Growth 819.581 | Return On Assets | Return On Equity |
Understanding Viridian Therapeutics requires distinguishing between market price and book value, where the latter reflects Viridian's accounting equity. The concept of intrinsic value - what Viridian Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Viridian Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Viridian Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Viridian Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Viridian Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Viridian Therapeutics.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in Viridian Therapeutics on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Viridian Therapeutics or generate 0.0% return on investment in Viridian Therapeutics over 90 days. Viridian Therapeutics is related to or competes with Uniqure NV, Structure Therapeutics, Edgewise Therapeutics, Galapagos, Ocular Therapeutix, Vera Therapeutics, and Arcus Biosciences. Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases More
Viridian Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Viridian Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Viridian Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.1 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 10.39 | |||
| Value At Risk | (3.92) | |||
| Potential Upside | 3.71 |
Viridian Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Viridian Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Viridian Therapeutics' standard deviation. In reality, there are many statistical measures that can use Viridian Therapeutics historical prices to predict the future Viridian Therapeutics' volatility.| Risk Adjusted Performance | 0.0201 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0407 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Viridian Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Viridian Therapeutics February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0201 | |||
| Market Risk Adjusted Performance | 0.0507 | |||
| Mean Deviation | 1.72 | |||
| Semi Deviation | 2.03 | |||
| Downside Deviation | 2.1 | |||
| Coefficient Of Variation | 5880.73 | |||
| Standard Deviation | 2.21 | |||
| Variance | 4.87 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0407 | |||
| Maximum Drawdown | 10.39 | |||
| Value At Risk | (3.92) | |||
| Potential Upside | 3.71 | |||
| Downside Variance | 4.42 | |||
| Semi Variance | 4.12 | |||
| Expected Short fall | (1.81) | |||
| Skewness | 0.2762 | |||
| Kurtosis | 0.2355 |
Viridian Therapeutics Backtested Returns
Viridian Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of close to zero, which indicates the firm had a close to zero % return per unit of risk over the last 3 months. Viridian Therapeutics exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Viridian Therapeutics' Risk Adjusted Performance of 0.0201, semi deviation of 2.03, and Coefficient Of Variation of 5880.73 to confirm the risk estimate we provide. The entity has a beta of 0.68, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Viridian Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Viridian Therapeutics is expected to be smaller as well. At this point, Viridian Therapeutics has a negative expected return of -0.0211%. Please make sure to validate Viridian Therapeutics' downside variance, as well as the relationship between the accumulation distribution and market facilitation index , to decide if Viridian Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.41 |
Average predictability
Viridian Therapeutics has average predictability. Overlapping area represents the amount of predictability between Viridian Therapeutics time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Viridian Therapeutics price movement. The serial correlation of 0.41 indicates that just about 41.0% of current Viridian Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.41 | |
| Spearman Rank Test | 0.06 | |
| Residual Average | 0.0 | |
| Price Variance | 3.57 |
Pair Trading with Viridian Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Viridian Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viridian Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Viridian Stock
The ability to find closely correlated positions to Viridian Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Viridian Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Viridian Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Viridian Therapeutics to buy it.
The correlation of Viridian Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Viridian Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Viridian Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Viridian Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Viridian Therapeutics Correlation, Viridian Therapeutics Volatility and Viridian Therapeutics Performance module to complement your research on Viridian Therapeutics. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Viridian Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.